登录 | 注册    关注公众号  
微信公众号
搜索
 >  Protein>FGF basic >BFF-H4117

Human FGF basic Protein, premium grade

GMP version GMP-FGCH17 is now available for seamless transition.

分子别名(Synonym)

FGF2,BFGF,FGFB,FGF basic,HBGF-2

表达区间及表达系统(Source)

Human FGF basic, premium grade (BFF-H4117) is expressed from E. coli cells. It contains AA Pro 143 - Ser 288 (Accession # P09038-4).

Predicted N-terminus: Pro 143

It is produced under our rigorous quality control system that incorporates a comprehensive set of tests including sterility and endotoxin tests. Product performance is carefully validated and tested for compatibility for cell culture use or any other applications in the early preclinical stage.
GMP-FGCH17 is the GMP version of this BFF-H4117. These two proteins display indistinguishable performance profiles, thereby ensuring a seamless transition for end users from early preclinical stag to later clinical phases.

Request for sequence

蛋白结构(Molecular Characterization)

FGF basic Structure

This protein carries no "tag".

The protein has a calculated MW of 16.5 kDa. The protein migrates as 17 kDa±3 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE).

内毒素(Endotoxin)

Less than 0.01 EU per μg by the LAL method.

宿主蛋白残留(Host Cell Protein)

<0.5 ng/µg of protein tested by ELISA.

宿主核酸残留(Host Cell DNA)

<0.02 ng/μg of protein tested by qPCR.

无菌(Sterility)

Negative

支原体(Mycoplasma)

Negative.

纯度(Purity)

>95% as determined by SDS-PAGE.

>95% as determined by SEC-HPLC.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -20°C to -70°C for 24 months in lyophilized state;
  2. -70°C for 3 months under sterile conditions after reconstitution.

质量管理控制体系(QMS)

  1. 质量管理体系(ISO, GMP)
  2. 质量优势
  3. 质控流程
 

电泳(SDS-PAGE)

FGF basic SDS-PAGE

Human FGF basic, premium grade on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).

SEC-HPLC

FGF basic SEC-HPLC

The purity of Human FGF basic, premium grade (Cat. No. BFF-H4117) was greater than 95% as determined by SEC-HPLC.

 

活性(Bioactivity)-CELL BASE

FGF basic CELL

Human FGF basic, premium grade (Cat. No. BFF-H4117) stimulates proliferation of NIH/3T3 cells. The specific activity of Human FGF basic, premium grade is > 2.50×10^6 IU/mg, which is calibrated against human FGF basic WHO International Standard (NIBSC code: 90/712) (QC tested).

Protocol

 

活性(Bioactivity)-ELISA

FGF basic ELISA

Immobilized Human FGF basic, premium grade (Cat. No. BFF-H4117) at 5 μg/mL (100 μL/well) can bind Human Glypican 3 Protein, Fc Tag (Cat. No. GP3-H5258) with a linear range of 0.3-5 ng/mL (QC tested).

Protocol

FGF basic ELISA

Immobilized Human FGF basic, premium grade (Cat. No. BFF-H4117) at 5 μg/mL (100 μL/well) can bind Human Glypican 1, Fc Tag (Cat. No. GP1-H5254) with a linear range of 1-20 ng/mL (Routinely tested).

Protocol

 

稳定性(Stability)

FGF basic STABILITY

The Cell based assay shows that Human FGF basic, premium grade (Cat. No. BFF-H4117) is stable at 37℃ for 48 hours.

FGF basic STABILITY

The Cell based assay shows that Human FGF basic, premium grade (Cat. No. BFF-H4117) is stable after freezing and thawing 3 times.

FGF basic STABILITY

The Cell based assay shows batch-to-batch consistency between Acro's GMP and PG FGF basic.

 
评论(2)
 
ACRO质量管理体系
 
 

背景(Background)

FGF basic is a member of the FGF family of at least 23 related mitogenic proteins which show 35-60% amino acid conservation. FGF acidic and basic, unlike the other members of the family, lack signal peptides and are apparently secreted by mechanisms other than the classical protein secretion pathway. FGF basic has been isolated from a number of sources, including neural tissue, pituitary, adrenal cortex, corpus luteum, and placenta. This factor contains four cysteine residues, but reduced FGF basic retains full biological activity, indicating that disulfide bonds are not required for this activity. bFGF is a critical component of human embryonic stem cell culture medium; the growth factor is necessary for the cells to remain in an undifferentiated state, although the mechanisms by which it does this are poorly defined. It has been demonstrated to induce gremlin expression which in turn is known to inhibit the induction of differentiation by bone morphogenetic proteins. It is necessary in mouse-feeder cell dependent culture systems, as well as in feeder and serum-free culture systems.

文献引用(Citations)

 

前沿进展

Safety and efficacy of long term asfotase alfa treatment in childhood hypophosphatasia
d'Angelo, Lauriola, Silvestrini et al
Ital J Pediatr (2025) 51 (1), 86
Abstract: Hypophosphatasia (HPP) is a rare inherited disorder characterized by a deficiency of tissue-non-specific alkaline phosphatase (TNSALP) due to loss-of-function variants of the ALPL gene. HPP is characterized by an extremely variable age of onset and clinical presentation, largely depending on the type of genetic disruption. Childhood HPP commonly presents with skeletal deformities, bone fragility, precocious tooth loss, muscle weakness and sometimes neurological implications. Laboratory tests usually document low levels of alkaline phosphatase (ALP), and radiologic investigations show peculiar bone abnormalities. Treatment with human recombinant TNSALP (asfotase alpha, Strensiq®), available since 2015, is associated with a sudden improvement and a good safety profile.A previously healthy 15-month-old girl presented with progressive "genu valgus" and sudden limping. The patient was diagnosed with childhood HPP due to the presence of two ALPL variants, never described in compound heterozygosity: a missense variant c.571G > A, p.(Glu191Lys), and a frameshift deletion c.963delG; p.(Lys322Argfs*44), both classified as pathogenetic. The child was promptly treated with asfotase alpha, and good improvement was quickly obtained. Efficacy, safety, and good tolerance persisted after a long-term follow-up of 6 years.Pediatricians should consider HPP in children presenting with a suggestive clinical phenotype. Calcium-phosphorus metabolism, ALP, and vitamin B6 should always be investigated in suspected cases. Moreover, asfotase alfa represents a safe, well-tolerated, and effective drug in children with HPP.© 2025. The Author(s).
Hindlimb unloading reversibly attenuates osteogenic potential of rat skeletal stem and progenitor cells ex vivo
Markina, Andreeva, Buravkova
Cells Tissues Organs (2025)
Abstract: Prolonged space flights negatively affect skeleton. Stromal cells of mesenchymal origin play a crucial role in maintaining homeostasis and in regulating the physiological remodeling of various tissues, and this has particular significance for bone.Hindlimb unloading (HU) of rats as a ground-based model for simulation of microgravity was implemented. The functional activity of skeletal stem and progenitor cells (SSPCs) from rat femoral bones was assessed in vitro after 2 weeks of HU and after 2 weeks of subsequent recovery of load support (HU+R). To characterize the growth of the SSPCs, the number of population doublings (PD) was calculated. Histochemical detection of the activity of alkaline phosphatase (AP) - an early marker of osteo-differentiation - on day 7, and of extracellular matrix (ECM) mineralization - as a sign of late osteo-differentiation - on day 21, were carried out. Quantitative real-time PCR was performed to detect the expression of the genes encoding proteins associated with the functional activity of osteoprogenitor cells (Pparg, Runx2, Alpl, Cxcl12) and bone tissue homeostasis (Mmp9, Spp1, RANKL, OPG, Ibsp, BMP10, Sost).After HU, a decrease in AP activity and a significant attenuation of extracellular matrix mineralization were detected. There was also significant downregulation of the genes those for bone matrix proteins (RANKL, OPG, Ibsp), and of the master-genes controlling osteo- and adipo-differentiation (Runx2, Alpl), as well as of Mmp9, encoding a regulatory molecule of bone matrix remodeling. By contrast, sclerostin (Sost) was upregulated. After HU+R, the PD, an AP activity and the level of extracellular matrix mineralization were restored.HU leads to inhibition of the osteoplastic function of SSPCs. The presented data are significant for the elucidation of microgravity-induced mechanisms of bone impairment and for the development of countermeasures for astronauts as well as for osteo-deficient patients after prolonged immobilization.S. Karger AG, Basel.
Current Perspectives on Additive Manufacturing and Titanium Surface Nanotopography in Bone Formation
da Costa Valente, Uehara, Lisboa Batalha et al
J Biomed Mater Res B Appl Biomater (2025) 113 (3), e35554
Abstract: This study aimed to assess the impact of manufacturing methods (conventional and additive manufacturing) and surface treatments (polished and nanotopographic) on the physicochemical properties of Ti6Al4V alloy and their correlation with osteoblast cellular behavior. The evaluated groups were Machined Discs (MD), Machined Discs with Treatment (MD-WT), Additive-manufactured Discs (AD), and Additive-manufactured Discs with Treatment (AD-WT). Surface analyses included SEM, AFM, surface roughness, EDS, XRD, surface free energy, and zeta potential. MC3T3-E1 cells were cultured for biological assessments, including cell morphology, viability, gene expression, alkaline phosphatase activity, and mineralization. ANOVA and Holm-Sidak tests were applied (p < 0.05). MD exhibited grooved topography, AD had partially fused spherical particles, while MD-WT and AD-WT showed patterns from chemical treatment (H3PO4 + NaOH). EDS identified additional ions in MD-WT and AD-WT. XRD patterns indicated crystal lattice orientation differences. MD-WT and AD-WT displayed higher surface free energy than MD and AD (p < 0.05). AD had greater roughness (Sa 6.98 μm, p < 0.05). Biological analyses revealed higher cell viability for MD and AD (p < 0.001), higher ALP activity in MD, and lower in AD-WT. Gene expression varied, with MD showing higher Alpl, Ibsp, and Bglap (p < 0.001), and AD-WT showing higher Runx2 (p < 0.001). Mineralized matrix behavior was similar for MD, AD, and MD-WT (p > 0.05). MD and AD surfaces demonstrated superior osteogenic differentiation potential, while AD exhibited greater roughness, lower surface free energy, higher cell viability, and osteoblastic differentiation potential.© 2025 Wiley Periodicals LLC.
Long-Term Outcomes of Early Enzyme Replacement Therapy With Asfotase Alfa in Perinatal Benign Hypophosphatasia: Amelioration of Bone Deformities in a Young Child
Terayama, Kobayashi, Suemitsu et al
Cureus (2025) 17 (2), e78473
Abstract: Hypophosphatasia (HPP) is a congenital skeletal dysplasia. Enzyme replacement therapy (ERT) improves survival and bone mineralization of patients with perinatal severe HPP. However, there are few reports of ERT in patients with perinatal benign HPP, and its long-term efficacy remains unclear. Herein, we report the case of a boy with perinatal benign HPP who was initiated on early ERT with asfotase alpha. The patient was suspected of having HPP because of shortened limbs and deformed long bones on fetal 3D-CT. He was diagnosed with HPP based on clinical manifestations, low serum alkaline phosphatase levels, and ALPL gene variants. At the age of two years and three months, he had muscle weakness and motor developmental delay requiring support to walk, and ERT was initiated. His muscle strength improved immediately, and he could walk independently two months after starting ERT. Shortening and bowed limbs improved, and his body height increased from -3.48 SD (at the age of two years and three months) to -1.71 SD (at the age of nine years and eight months) after starting ERT. Hence, early ERT effectively improves motor development, bone deformity, and short stature in patients with perinatal benign HPP.Copyright © 2025, Terayama et al.
Showing 1-4 of 1229 papers.
Powered by BizGenius
 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
FGF basic靶点信息
英文全称:Fibroblast growth factor 2
中文全称:成纤维细胞生长因子2
种类:Homo sapiens
上市药物数量:1详情
临床药物数量:3详情
最高研发阶段:批准上市
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定